Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
The effect of drug concentration and light on the compatibility and stability of cisplatin and fluorouracil in i.v. admixtures was studied. Two sets of admixtures were prepared in 0.9% sodium chloride injection in polyvinyl chloride bags--(1) cisplatin 200 micrograms/mL and fluorouracil 1,000 micrograms/mL and (2) cisplatin 500 micrograms/mL and fluorouracil 10,000 micrograms/mL. Half of the admixtures were protected from light. All admixtures were stored at room temperature (24-26 degrees C), and those admixtures not protected from light were stored under room fluorescent light. After visual inspection, the pH of each admixture was determined, and an aliquot was assayed for drug concentration using a stability-indicating high-performance liquid chromatographic assay. Over a four-hour period, no visual changes were observed and the pH changes observed were negligible. In admixtures containing the lower concentrations of cisplatin and fluorouracil, it took approximately 1.5 hours for the concentration of cisplatin to reach 90% of the initial concentration. By four hours (lower concentration range) and three hours (higher concentration range) after the admixtures were prepared, less than 75% of the initial cisplatin concentration remained. There was less than a 5% decrease measured in the fluorouracil concentrations over the observation time. Admixtures of cisplatin and fluorouracil in 0.9% sodium chloride injection at the concentrations evaluated in this study must be used within one hour of preparation, whether or not they are protected from light. Intravenous administration of fluorouracil and cisplatin by continuous infusion will require alternative approaches to mixing the two drugs in the same container.
Stewart
C F
CF
Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis.
Fleming
R A
RA
D002626:Chemistry, Pharmaceutical; D002945:Cisplatin / Q000008:administration & dosage*; D004344:Drug Incompatibility; D004349:Drug Packaging; D004355:Drug Stability; D005472:Fluorouracil / Q000008:administration & dosage*; D006863:Hydrogen-Ion Concentration; D012965:Sodium Chloride
D012965:Sodium Chloride; D002945:Cisplatin; D005472:Fluorouracil